Building a Prescription Cannabidiol Telehealth Brand Ahead of the Hemp Deadline — What You Need to Know

• The Hemp Reset: What's Changing and When — what the November 12 and December 11 deadlines actually change, who they affect, and why a prescription pathway, regulated under pharmacy law rather than the hemp definition, isn't touched by either one
• The Market Opportunity — the gap between what most cannabidiol users take today (54% under 50mg a day) and the doses studied in clinical research (200–400mg), and how big that gap makes the opportunity for a clinician-led model
• Clinical & Pharmacy Considerations for Operators — what pharmaceutical-grade, THC-free cannabidiol actually requires: a decade of purification science, third-party testing, condition-specific dosing protocols, and 503A compounding
• Business Considerations for Operators — how a hemp or cannabidiol brand keeps its storefront, identity, and existing customer relationships while moving into a regulated pathway, and how operators differentiate as more brands make the move

Whether you're evaluating a prescription cannabidiol pathway for your program or trying to understand what it actually takes to build one before the deadline, this session will give you the clearest picture available right now.